André Nicolás León

André Nicolás León

Auto-generated profile, based on publicly available information

André Nicolás León

Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 April 2024 in npj Vaccines
Verified
Journal Article
Open access
PDF file
IMIván Moral-Sánchez
Iván Moral-Sánchez
EWEdmund G. Wee
Edmund G. Wee
YXYuejiao Xian
Yuejiao Xian
WLWen-Hsin Lee
Wen-Hsin Lee
JAJoel D. Allen
Joel D. Allen
RSRogier W. Sanders
Rogier W. Sanders
Recombinant native-like HIV-1 envelope glycoprotein (Env) trimers are used in candidate vaccines aimed at inducing broadly neutralizing antibodies. While state-of-the-art SOSIP or single-chain Env designs can be expressed as native-like trimers, undesired monomers, dimers and malformed trimers that elicit non-neutralizing antibodies are also formed, implying that these designs could benefit from further modifications for gene-based vaccination approaches. Here, we describe the triple tandem trimer (TTT) design, in which three Env protomers are genetically linked in a single open reading frame and express as native-like trimers. Viral vectored Env TTT induced similar neutralization titers but with a higher proportion of trimer-specific responses. The TTT design was also applied to generate influenza hemagglutinin (HA) trimers without the need for trimerization domains. Additionally, we used TTT to generate well-folded chimeric Env and HA trimers that harbor protomers from three different strains. In summary, the TTT design is a useful platform for the design of HIV-1 Env and influenza HA immunogens for a multitude of vaccination strategies.

13 December 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
GAGarazi Peña Alzua
Garazi Peña Alzua
ALAndré Nicolás León
André Nicolás León
TYTemima Yellin
Temima Yellin
DBDisha Bhavsar
Disha Bhavsar
MLMadhumathi Loganathan
Madhumathi Loganathan
Florian KrammerFlorian Krammer
Florian Krammer
The highly pathogenic avian influenza H5N1 virus clade 2.3.4.4b has been spreading globally since 2022, causing mortality and morbidity in domestic and wild birds, as well as in mammals, which underscores its potential to cause a pandemic. Here, we generate a panel of anti-hemagglutinin (HA) human monoclonal antibodies (mAbs) against the H5 protein of clade 2.3.4.4b. To develop human chimeric antibodies, H2L2 Harbor Mice®, which express human immunoglobulin germline genes, were immunized with H5 and N1 recombinant proteins from A/mallard/New York/22-008760-007- original/2022 H5N1 virus. Through hybridoma technology, sixteen fully human mAbs are generated, most of which show cross-reactivity against H5 proteins from different clade 2.3.4.4 virus variants. Fourteen out of the sixteen mAbs neutralize the virus in vitro. The mAbs with the strongest hemagglutination inhibition activity also demonstrate greater neutralizing capacity and show increased protective effects in vivo when administered prophylactically or therapeutically in a murine H5N1 challenge model. Using cryo-electron microscopy, we identify a cross-clonotype conserved motif that bound a hydrophobic groove on the head domain of H5 HA. Akin to mAbs against severe acute respiratory syndrome coronavirus 2 during the coronavirus 2019 pandemic, these mAbs could serve as treatments in case of a widespread H5N1 epidemic or pandemic.

12 March 2025 in mBio
Verified
Journal Article
Open access
ALAndré Nicolás León
André Nicolás León
ARAlesandra J. Rodriguez
Alesandra J. Rodriguez
SRSara T. Richey
Sara T. Richey
APAlba Torrents de la Pena
Alba Torrents de la Pena
RWRachael M. Wolters
Rachael M. Wolters
AWAndrew Ward
Andrew Ward
Cellular and molecular characterization of immune responses elicited by influenza virus infection and seasonal vaccination have informed efforts to improve vaccine efficacy, breadth, and longevity. Here, we use negative stain electron microscopy polyclonal epitope mapping (nsEMPEM) to structurally characterize the humoral IgG antibody responses to hemagglutinin (HA) from human patients vaccinated with a seasonal quadrivalent flu vaccine or infected with influenza A viruses. Our data show that both vaccinated and infected patients had humoral IgGs targeting highly conserved regions on both H1 and H3 subtype HAs, including the stem and anchor, which are targets for universal influenza vaccine design. Responses against H1 predominantly targeted the central stem epitope in infected patients and vaccinated donors, whereas head epitopes were more prominently targeted on H3. Responses against H3 were less abundant, but a greater diversity of H3 epitopes were targeted relative to H1. While our analysis is limited by sample size, on average, vaccinated donors responded to a greater diversity of epitopes on both H1 and H3 than infected patients. These data establish a baseline for assessing polyclonal antibody responses in vaccination and infection, providing a context for future vaccine trials and emphasizing the need for further characterization of protective responses toward conserved epitopes. (201 words) IMPORTANCE: Seasonal influenza viruses cause hundreds of thousands of deaths each year and up to a billion infections; under the proper circumstances, influenza A viruses with pandemic potential could threaten the lives of millions more. The variable efficacies of traditional influenza virus vaccines and the desire to prevent pandemic influenzas have motivated work toward finding a universal flu vaccine. Many promising universal flu vaccine candidates currently focus on guiding immune responses to highly conserved epitopes on the central stem of the influenza hemagglutinin viral fusion protein. To support the further development of these stem-targeting vaccine candidates, in this study, we use negative stain electron microscopy to assess the prevalence of central stem-targeting antibodies in individuals who were exposed to influenza antigens through traditional vaccination and/or natural infection during the 2018–2019 flu season.

1 May 2026 in Communications Medicine
Verified
Journal Article
Open access
AFAnnette Fox
Annette Fox
AAAnnette Alafaci
Annette Alafaci
LCLouise Carolan
Louise Carolan
RBRebecca Burrell
Rebecca Burrell
SSStephany Sánchez-Ovando
Stephany Sánchez-Ovando
KSKanta Subbarao
Kanta Subbarao
Annual influenza vaccination is recommended for young children with limited understanding of how this may imprint influenza immunity. We conducted a pilot study to examine whether early life exposure to influenza through vaccination versus infection affects subsequent vaccination responses. Nineteen children aged 6-60 months were enrolled at two Australian hospitals during 2019-2021. Plasma was collected before and after vaccination for up to three successive years to measure antibody titres by hemagglutinination (HA) and neuraminidase (NA) inhibiting (HI, NI) assays and ELISA. Medical records and seropositivity (HI titre ≥40) at enrolment were used to classify seven children as having prior vaccination(s) and eight as having prior influenza A(H3N2) infection. Others had mixed, no, or unclear prior exposures. Post-vaccination antibody titres and seroconversion (HI fold-rise ≥4) were compared across the two main prior exposure groups. Here we show that post-vaccination HI and NI antibody titres and titre-rises against A(H3N2) are far higher among children classified as having had prior A(H3N2) infection compared to prior vaccination; 8/8 versus 3/7 seroconverted, respectively. A(H3N2) HA-stem binding antibody titres are modest but rise more after vaccination among children classified as having had prior A(H3N2) infection. A(H1N1)-reactive antibody responses are not significantly different between groups. These results suggest that for priming subsequent vaccine antibody responses against A(H3N2), infection may be superior to vaccination.

11 July 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
ALAndré Nicolás León
André Nicolás León
ARAlesandra J. Rodriguez
Alesandra J. Rodriguez
SRSara T. Richey
Sara T. Richey
APAlba Torrents de la Peña
Alba Torrents de la Peña
RWRachael M. Wolters
Rachael M. Wolters
AWAndrew Ward
Andrew Ward
Cellular and molecular characterization of immune responses elicited by influenza virus infection and seasonal vaccination have informed efforts to improve vaccine efficacy, breadth, and longevity. Here, we use negative stain electron microscopy polyclonal epitope mapping (nsEMPEM) to structurally characterize the humoral IgG antibody responses to hemagglutinin (HA) from human patients vaccinated with a seasonal quadrivalent flu vaccine or infected with influenza A viruses. Our data show that both vaccinated and infected patients had humoral IgGs targeting highly conserved regions on both H1 and H3 subtype HAs, including the stem and anchor, which are targets for universal influenza vaccine design. Responses against H1 predominantly targeted the central stem epitope in infected patients and vaccinated donors, whereas head epitopes were more prominently targeted on H3. Responses against H3 were less abundant, but a greater diversity of H3 epitopes were targeted relative to H1. While our analysis is limited by sample size, on average, vaccinated donors responded to a greater diversity of epitopes on both H1 and H3 than infected patients. These data establish a baseline for assessing polyclonal antibody responses in vaccination and infection, providing context for future vaccine trials and emphasizing the importance of carefully designing vaccines to boost protective responses towards conserved epitopes.

1 July 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
DBDisha Bhavsar
Disha Bhavsar
ALAndré Nicolás León
André Nicolás León
WHWei-Li Hsu
Wei-Li Hsu
EPEduard Puente-Massaguer
Eduard Puente-Massaguer
JFJames A. Ferguson
James A. Ferguson
Florian KrammerFlorian Krammer
Florian Krammer
SUMMARY: Avian H15 influenza viruses are closely related to H7 viruses, but feature a unique 9-amino acid insertion in their hemagglutinin head domain, creating an additional site for antigenic variation. Here, we characterized a panel of mouse monoclonal antibodies (mAbs) raised against the A/wedge-tailed shearwater/Western Australia/2576/1979 ancestral strain, and a human mAb isolated from an H7N9 vaccinee. We found differences in binding and neutralization profiles against the ancestral strain and drifted strains of H15 isolated after 2008. MAbs that have hemagglutination inhibition activity against the ancestral strain do not show binding to drifted strains, hinting at antigenic differences in the receptor binding site. We show that the mAbs protect in vivo and elucidate mAb-antigen interactions using negative stain and cryo-electron microscopy. The characterization of H15 antigenicity and mechanisms of antibody-mediated neutralization expands our knowledge of this rare avian influenza virus and informs our understanding of immune pressures on viral surface glycoproteins.